Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder

Completed · Phase 4

Conditions studied: ADHD, Bipolar Disorder

In brief

The objective of this study is to investigate the safety and effectiveness of Concerta in the treatment of children (ages 5 to 17 years old) and adults (ages 18 to 55 years old) with Bipolar I, Bipolar II and Bipolar Spectrum Disorder and comorbid ADHD over 8 weeks. This study seeks to study the short-term effectiveness of a long acting formulation of methylphenidate (Concerta) in the treatment of children and adults with bipolar disorder and comorbid ADHD adequately stabilized on an acceptable and stable regimen of anti-mania agents.

Key facts

Study ID: NCT00181987
Run by: Massachusetts General Hospital
People needed: 29
Starts: 2002-08-01
Expected to finish: 2005-08-01
Last updated by the study team: 2013-10-22

Who can join

Age: 6 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female subjects, 5-55 years of age.
Each subject, as well as the legal representative for children under the age of 18, must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
Each subject (and his/her authorized legal representative, if applicable) must understand the nature of the study. The subject's authorized legal representative must sign an informed consent document and the study participant must sign an informed assent document.
Subjects must have a diagnosis of Bipolar I, Bipolar II, Bipolar NOS or sub-threshold Bipolar Disorder with a stable Young Mania Scale rating of < 15 for at least one month, a Depression CGI-Severity score < 3 (mildly ill), a score on the Hamilton Depression Rating Scale below 15 (mild range), and a comorbid diagnosis of ADHD according to the DSM-IV based on clinical assessment and confirmed by structured diagnostic interview (Kiddie Schedule of Affective Disorders or Structured Clinical Interview DSM-IV), subjects may not have expressed symptoms for past 20 years.
Subject must be able to participate in mandatory blood draws.
Subject must be able to swallow pills.

You may not qualify if…

Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild.
Serious, unstable illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease
Uncorrected hypothyroidism or hyperthyroidism.
History of severe allergies or multiple adverse drug reactions.
Non-febrile seizures without a clear and resolved etiology.
Leukopenia or history of leukopenia without a clear and resolved etiology.
Judged clinically to be at serious suicidal risk.
Any other concomitant medication with primarily central nervous system activity other than specified in Concomitant Medication portion of the protocol
History of intolerance or non-responder to Concerta as determined by the principal investigator.
Treatment with nonreversible monoamine oxidase inhibitor within 2 weeks prior to initiation of study.
Current diagnosis of schizophrenia. 12. Diagnosis of any chronic motor or vocal tic, or Tourette's Syndrome.

Where it is running

Massachusetts General Hospital — Cambridge, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.